TY - JOUR
T1 - Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML
T2 - a narrative review
AU - Vegivinti, Charan Thej Reddy
AU - Keesari, Praneeth Reddy
AU - Veeraballi, Sindhusha
AU - Martins Maia, Catarina Maria Pina
AU - Mehta, Ansh Krishnachandra
AU - Lavu, Rohit Reddy
AU - Thakur, Rahul Kumar
AU - Tella, Sri Harsha
AU - Patel, Riya
AU - Kakumani, Venkata Kiranmayi
AU - Pulakurthi, Yashwitha Sai
AU - Aluri, Srinivas
AU - Aggarwal, Ritesh Kumar
AU - Ramachandra, Nandini
AU - Zhao, Rongbao
AU - Sahu, Srabani
AU - Shastri, Aditi
AU - Verma, Amit
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Dysregulation of the innate immune system and inflammatory-related pathways has been implicated in hematopoietic defects in the bone marrow microenvironment and associated with aging, clonal hematopoiesis, myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). As the innate immune system and its pathway regulators have been implicated in the pathogenesis of MDS/AML, novel approaches targeting these pathways have shown promising results. Variability in expression of Toll like receptors (TLRs), abnormal levels of MyD88 and subsequent activation of NF-κβ, dysregulated IL1-receptor associated kinases (IRAK), alterations in TGF-β and SMAD signaling, high levels of S100A8/A9 have all been implicated in pathogenesis of MDS/AML. In this review we not only discuss the interplay of various innate immune pathways in MDS pathogenesis but also focus on potential therapeutic targets from recent clinical trials including the use of monoclonal antibodies and small molecule inhibitors against these pathways.
AB - Dysregulation of the innate immune system and inflammatory-related pathways has been implicated in hematopoietic defects in the bone marrow microenvironment and associated with aging, clonal hematopoiesis, myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). As the innate immune system and its pathway regulators have been implicated in the pathogenesis of MDS/AML, novel approaches targeting these pathways have shown promising results. Variability in expression of Toll like receptors (TLRs), abnormal levels of MyD88 and subsequent activation of NF-κβ, dysregulated IL1-receptor associated kinases (IRAK), alterations in TGF-β and SMAD signaling, high levels of S100A8/A9 have all been implicated in pathogenesis of MDS/AML. In this review we not only discuss the interplay of various innate immune pathways in MDS pathogenesis but also focus on potential therapeutic targets from recent clinical trials including the use of monoclonal antibodies and small molecule inhibitors against these pathways.
KW - Acute myeloid leukemia (AML)
KW - IL1 receptor Associated kinase (IRAK)
KW - Inflammasome
KW - Innate Immune pathways
KW - Myelodysplastic syndromes (MDS)
KW - Toll like receptors (TLRs)
KW - Tumor microenvironment (TME)
UR - http://www.scopus.com/inward/record.url?scp=85164131693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85164131693&partnerID=8YFLogxK
U2 - 10.1186/s40164-023-00422-1
DO - 10.1186/s40164-023-00422-1
M3 - Review article
AN - SCOPUS:85164131693
SN - 2162-3619
VL - 12
JO - Experimental Hematology and Oncology
JF - Experimental Hematology and Oncology
IS - 1
M1 - 60
ER -
